Buscar
LENZ Therapeutics Inc
LENZAñadir a la lista de seguimiento
3.710USD
-0.050-1.33%
Horarios del mercado 09/24, 13:44（ET）
116.31MCap. mercado
PérdidaP/E TTM
Acerca de LENZ Therapeutics Inc Compañía
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Perfil de LENZ Therapeutics Inc
Símbolo de cotizaciónLENZ
Nombre de la empresaLENZ Therapeutics Inc
Fecha de salida a bolsaJun 25, 2021
Director ejecutivoSchimmelpennink (Evert)
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónLENZ
Fecha de salida a bolsaJun 25, 2021
Director ejecutivoSchimmelpennink (Evert)
Ejecutivos de LENZ Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de LENZ Therapeutics Inc?
Los cinco principales accionistas de LENZ Therapeutics Inc son: Mr. Marc Odrich
¿Cuántas instituciones poseen acciones de LENZ Therapeutics Inc (LENZ)?
A fecha de 2026Q1, 347 instituciones poseen acciones de LENZ Therapeutics Inc, con un valor de mercado combinado de aproximadamente 36.30M, lo que representa el 115.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 853081.00.